Drug profile · INN
rozanolixizumab
RYSTIGGO
rozanolixizumab (RYSTIGGO) is a igg receptor fcrn large subunit p51 inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L04) L04AL02
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — rozanolixizumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
rozanolixizumab (RYSTIGGO) is a igg receptor fcrn large subunit p51 inhibitor.
Key facts
INN rozanolixizumab
Brand RYSTIGGO
Mechanism IgG receptor FcRn large subunit p51 inhibitor
Target IgG receptor FcRn large subunit p51
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AL02
Mechanism of action
IgG receptor FcRn large subunit p51 inhibitor
Primary target: IgG receptor FcRn large subunit p51
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rozanolixizumab?
rozanolixizumab (RYSTIGGO) is a igg receptor fcrn large subunit p51 inhibitor.
What is the brand name for rozanolixizumab?
RYSTIGGO is a marketed brand name for rozanolixizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.